Search results for "Variants"

showing 10 items of 227 documents

Genome-wide association and longitudinal analyses reveal genetic loci linking pubertal height growth, pubertal timing and childhood adiposity

2013

The pubertal height growth spurt is a distinctive feature of childhood growth reflecting both the central onset of puberty and local growth factors. Although little is known about the underlying genetics, growth variability during puberty correlates with adult risks for hormone-dependent cancer and adverse cardiometabolic health. The only gene so far associated with pubertal height growth, LIN28B, pleiotropically influences childhood growth, puberty and cancer progression, pointing to shared underlying mechanisms. To discover genetic loci influencing pubertal height and growth and to place them in context of overall growth and maturation, we performed genome-wide association meta-analyses i…

MaleNetherlands Twin Register (NTR)Genetic LinkageMedizinGene ExpressionGenome-wide association studyVARIANTSBody Mass Index0302 clinical medicinegenetic linkageTransforming Growth Factor betaNeoplasmsmolecular biologygeneticsChildGenetics (clinical)Adiposity2. Zero hunger0303 health sciencesadiposityMitogen-Activated Protein Kinase 3Association Studies ArticlesAge FactorsACHONDROPLASIAGeneral MedicineGenome-Wide Association Study; pubertal height growth; pubertal timingPhenotypeOBESITYMenarche/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingbody heightFemaleSignal Transductionmedicine.medical_specialtyage factorsCHROMOSOME 16P11.2AdolescentBIRTHQuantitative Trait Loci030209 endocrinology & metabolismContext (language use)BiologyChildhood obesitypubertal height growthMENARCHEYoung Adult03 medical and health sciencesAGESDG 3 - Good Health and Well-beingPrepubertyInternal medicineGeneticsmedicine/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_HumansMolecular Biology030304 developmental biologySignMenarcheFACTOR RECEPTOR-3MUTATIONSpubertal timingPubertyta3121medicine.diseaseObesityBody HeightGenetic architectureEndocrinologyPOPULATION COHORTgene expressionBody mass indexFollow-Up StudiesGenome-Wide Association Study
researchProduct

Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency.

2012

We report 2 asymptomatic homozygotes for the nonsense p.R462X mutation affecting the carboxy-terminus of coagulation factor VII (FVII, 466 aminoacids). FVII levels of 3-5% and 2.7 ± 0.4% were found in prothrombin time-based and activated factor X (FXa) generation assays with human thromboplastins. Noticeably, FVII antigen levels were barely detectable (0.7 ± 0.2%) which suggested a gain-of-function effect. This effect was more pronounced with bovine thromboplastin (4.8 ± 0.9%) and disappeared with rabbit thromboplastin (0.7 ± 0.2%). This suggests that the mutation influences tissue factor/FVII interactions. Whereas the recombinant rFVII-462X variant confirmed an increase in specific activit…

MaleProteasesHeterozygoteFactor VII DeficiencyEnzyme-Linked Immunosorbent AssayFVIIBiologymedicine.disease_causeThromboplastinTissue factorchemistry.chemical_compoundCarboxy-terminalhemic and lymphatic diseasesmedicineFACTOR VII DEFICIENCY MOLECULAR VARIANTSThromboplastinMissense mutationAnimalsHumanscardiovascular diseasesChildBlood CoagulationProthrombin timeMutationmedicine.diagnostic_testFactor VIIHomozygoteHematologyFactor VIIMiddle AgedMolecular biologyAsymptomatic; Carboxy-terminal; FVII; Mutation;AsymptomaticchemistryCoagulationCodon NonsenseMutationMutagenesis Site-DirectedProthrombin TimeCattleFemaleRabbitsOriginal Articles and Brief Reports
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.

2015

Background: Monogenic hypertriglyceridemia (HTG) may result from mutations in some genes which impair the intravascular lipolysis of triglyceride (TG)-rich lipoproteins mediated by the enzyme Lipoprotein lipase (LPL). Mutations in the LPL gene are the most frequent cause of monogenic HTG (familial chylomicronemia) with recessive transmission. Methods: The LPL gene was resequenced in 149 patients with severe HTG (TG>10mmol/L) and 106 patients with moderate HTG (TG>4.5 and <10mmol/L) referred to tertiary Lipid Clinics in Italy. Results: In the group of severe HTG, 26 patients (17.4%) were homozygotes, 9 patients (6%) were compound heterozygotes and 15 patients (10%) were simple heter…

MaleSettore MED/09 - Medicina InternaDNA Mutational AnalysisFamilial chylomicronemia; Gene variants; Lipoprotein lipase; Pancreatitis; Primary hypertriglyceridemiaCompound heterozygositymedicine.disease_causeSeverity of Illness IndexPrimary hypertriglyceridemiaTertiary Care Centerschemistry.chemical_compoundGene FrequencyFamilial chylomicronemia; Gene variants; Lipoprotein lipase; Pancreatitis; Primary hypertriglyceridemia; Cardiology and Cardiovascular MedicineChildLipoprotein lipaseMutationHomozygoteMiddle AgedPhenotypeItalyChild PreschoolFemaleHyperlipoproteinemia Type ICardiology and Cardiovascular MedicineFamilial chylomicronemiaAdultmedicine.medical_specialtyGene variantHeterozygoteAdolescentBiologyGene variantsYoung AdultInternal medicinemedicineLipolysisHumansGenetic Predisposition to DiseaseTriglyceridesAgedPancreatitiTriglycerideHypertriglyceridemiaInfantHeterozygote advantageLipoprotein lipasemedicine.diseaseLipoprotein LipaseEndocrinologychemistryPancreatitisMutationPancreatitisBiomarkersAtherosclerosis
researchProduct

Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens

2014

To evaluate the concordance and prognostic role of histologic variants of bladder urothelial carcinoma in transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC) specimens. METHODS Clinicopathologic information available at the time of RC and follow-up data from 4110 RC specimens, collected between January 2000 and December 2009 at 17 tertiary referral centers were retrospectively analyzed and evaluated for the presence or absence of uncommon variants of bladder urothelial carcinoma. The presence or absence of uncommon variants of bladder urothelial carcinoma was evaluated on previous TURBT specimens of patients undergoing RC. Cox regression was used to assess the impac…

MaleURINARY-BLADDER; CANCER; UPDATE; IMPACT; DIFFERENTIATIONIMPACTmedicine.medical_treatmentKaplan-Meier EstimateSettore MED/24 - UrologiaRetrospective StudieBladder cancer histologic variantsbladder urothelial carcinomaUrinary bladderMedicine (all)Middle AgedPrognosisCANCERDIFFERENTIATIONmedicine.anatomical_structureTreatment OutcomeUrinary Bladder Neoplasmbladder cancerFemaleHumanmedicine.medical_specialtyPrognosiConcordanceUrologyUrinary BladderUrologyCystectomyDisease-Free SurvivalFollow-Up StudieCystectomymedicineCarcinomaHumansClinical significanceAged; Carcinoma; Cystectomy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urology; Medicine (all)Proportional Hazards ModelsRetrospective StudiesAgedBladder cancerProportional hazards modelbusiness.industryCarcinomaAged; Carcinoma; Cystectomy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder NeoplasmsCancermedicine.diseaseUrinary Bladder NeoplasmsProportional Hazards ModelUPDATEURINARY-BLADDERbusinessFollow-Up Studies
researchProduct

Novel association of the obesity risk-allele near Fas Apoptotic Inhibitory Molecule 2 (FAIM2) gene with heart rate and study of its effects on myocar…

2014

[Background] The Fas apoptotic pathway has been implicated in type 2 diabetes and cardiovascular disease. Although a polymorphism (rs7138803; G > A) near the Fas apoptotic inhibitory molecule 2 (FAIM2) locus has been related to obesity, its association with other cardiovascular risk factors and disease remains uncertain.

MalealelosEndocrinology Diabetes and MetabolismhumanosLOCIMyocardial Infarctionproteínas reguladoras de la apoptosisApoptosisType 2 diabetesVARIANTSDiet Mediterraneanestudios de seguimientoCoronary artery diseaseClinical trialsRisk FactorsMyocardial infarctionLongitudinal Studiesmediana edadOriginal Investigationeducation.field_of_studyancianoDiabetisdietaHàbits alimentarisCAUSE MORTALITYDiabetesSOLUBLE FASMiddle Agedestudios de asociación genéticaMEDITERRANEAN DIETCARDIOVASCULAR-DISEASECORONARY-ARTERY-DISEASEObesitatFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyFood habitsPopulationHeart rateproteínas de membranasMediterranean cookingDiabetes mellitusInternal medicineCuina mediterràniamedicineDiabetes MellitusHumansfactores de riesgoJAPANESE POPULATIONGenetic Predisposition to DiseaseObesityGENOME-WIDE ASSOCIATIONeducationobesidadAllelesGenetic Association Studiesinfarto de miocardioAgedPolymorphism Geneticbusiness.industryMembrane Proteinspredisposición genética a la enfermedadmedicine.diseaseObesityFAIM2DietBODY-MASS INDEXInfart de miocardiMyocardial infarctionEndocrinologyBlood pressureDiabetes Mellitus Type 2frecuencia cardíacaestudios longitudinalesbusinessApoptosis Regulatory ProteinsBody mass indexFollow-Up StudiesAssaigs clínics
researchProduct

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

2015

et al.

Maleendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryPapillaryAdult; Carcinoma; Carcinoma Papillary; Cohort Studies; Female; Follow-Up Studies; Gene Frequency; Humans; Male; Middle Aged; Neoplasm Metastasis; Prevalence; Prognosis; Radiotherapy; Retrospective Studies; Risk Assessment; Thyroid Cancer Papillary; Thyroid Neoplasms; Neoplasm Recurrence LocalThyroid CancerBiochemistryPapillary thyroid cancerCohort StudiesThyroid carcinoma Papillary Thyroid Carcinoma Variants Prognosis0302 clinical medicineEndocrinologyGene FrequencyInterquartile rangePrevalenceNeoplasm MetastasisMiddle AgedPrognosisDiabetes and MetabolismLocalThyroid Cancer Papillary030220 oncology & carcinogenesisFemaleCohort studyAdultmedicine.medical_specialtyBiochemistry; Clinical Biochemistry; Endocrinology; Biochemistry (medical); Endocrinology Diabetes and Metabolism030209 endocrinology & metabolismContext (language use)Risk AssessmentThyroid carcinoma03 medical and health sciencesInternal medicinemedicineCarcinomaHumansThyroid NeoplasmsRetrospective StudiesRadiotherapybusiness.industryBiochemistry (medical)CarcinomaCancerRetrospective cohort studyOriginal Articlesmedicine.diseaseCarcinoma PapillaryEndocrinologyNeoplasm RecurrenceNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population

2016

// Daniele Balasus 1, * , Michael Way 2, * , Caterina Fusilli 3 , Tommaso Mazza 3 , Marsha Y. Morgan 2 , Melchiorre Cervello 4 , Lydia Giannitrapani 1 , Maurizio Soresi 1 , Rosalia Agliastro 5 , Manlio Vinciguerra 2, 6 , Giuseppe Montalto 1, 4 1 Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy 2 Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, London, UK 3 IRCCS Casa Sollievo della Sofferenza, Bioinformatics Unit, San Giovanni Rotondo (FG), Italy 4 Institute of Biomedicine and Molecular Immunology, National Research Council (C.N.R.), Palermo, Italy 5 Immunohematology and Trans…

Malehepatitis C virusSettore MED/09 - Medicina InternaGenome-wide association studyCohort StudiesLiver diseasesingle nucleotide polymorphisms0302 clinical medicineGene FrequencyRisk FactorsEpidemiologyhepatitis C viruEndoplasmic Reticulum Chaperone BiPSicilyHeat-Shock ProteinsLiver NeoplasmsTransfusion medicineHepatitis Chepatocellular carcinomaMiddle Aged3. Good healthOncologyrisk factor030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemaleResearch Papergenetic variantmedicine.medical_specialtyCarcinoma HepatocellularGenotypeSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseAllelesAgedbusiness.industrygenetic variantsMembrane ProteinsLipasemedicine.diseasedigestive system diseasesSurgerybusiness
researchProduct

Symplectic Applicability of Lagrangian Surfaces

2009

We develop an approach to affine symplectic invariant geometry of Lagrangian surfaces by the method of moving frames. The fundamental invariants of elliptic Lagrangian immersions in affine symplectic four-space are derived together with their integrability equa- tions. The invariant setup is applied to discuss the question of symplectic applicability for elliptic Lagrangian immersions. Explicit examples are considered.

Mathematics - Differential GeometryPure mathematicsdifferential invariantsSymplectic vector spaceFOS: MathematicsSymplectomorphismMoment mapMathematics::Symplectic GeometryMathematical PhysicsMathematicsSymplectic manifoldapplicabilityLagrangian surfaceslcsh:MathematicsMathematical analysisSymplectic representationmoving frameslcsh:QA1-939Symplectic matrixaffine symplectic geometryAffine geometry of curvesDifferential Geometry (math.DG)Lagrangian surfaces; affine symplectic geometry; moving frames; differential invariants; applicability.Geometry and TopologyAnalysisSymplectic geometry
researchProduct

Une nouvelle méthode constructive des lois de comportement des matériaux composites à l'aide de la théorie des invariants

2005

International audience; On propose une nouvelle méthode constructive, systématique et générale des lois de comportement des milieux anisotropes appuyée sur la Théorie des invariants. On peut résumer la démarche adoptée de la manière suivante : l'ensemble V des variables et le groupe (fini) S des symétries matérielles étant supposés connus, on donne une borne au nombre des éléments d'une famille des générateurs possibles des invariants polynominaux de V sous S ; on donne la méthode pour construire ces élements ; on écrit sous une forme induisant une certaine unicité, dite forme normale, la décomposition de tout invariant polynominal de V sous S. Enfin à l'aide des critères de tensorialité, o…

Matériau anisotrope[ SPI.MAT ] Engineering Sciences [physics]/Materials[ PHYS.COND.CM-MS ] Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci][PHYS.COND.CM-MS]Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci]théorie des invariants[SPI.MAT] Engineering Sciences [physics]/Materialsloi de comportement[PHYS.COND.CM-MS] Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci][SPI.MAT]Engineering Sciences [physics]/Materials
researchProduct